Details checkedClinical trial listing onlyCheckedregistry

Hospital for Special Surgery Risedronate Study in OI-Related Hearing Loss

Also known as: Risedronate Oral Tablet, Actonel, Effects of Bisphosphonates on OI-Related Hearing Loss, NCT04152551

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 4

Status

Active

Target Gene

—

Route / Mode

Oral

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

adult, pediatric, syndromic, osteogenesis-imperfecta

Trial IDs

Mechanism

Recruiting Phase 4 pilot study evaluating oral risedronate/bisphosphonate treatment and hearing outcomes in osteogenesis imperfecta-related hearing loss.

Indications

Hearing Loss

Notes

Verified as an institution-led OI-related hearing-loss pilot study, not an industry risedronate hearing-loss program. Adult participants receive risedronate while pediatric groups are observational standard-care/control arms.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT04152551

Open

Key Events

2019-11-02

Registry lists actual start for risedronate/bisphosphonate OI-related hearing-loss study

Clinical Trials (1)

NCT04152551

Data Checks